{"name":"Kinnate Biopharma","slug":"kinnate","ticker":"KNTE","exchange":"NASDAQ","domain":"kinnatebio.com","description":"Kinnate Biopharma is a precision oncology company focused on developing targeted therapies for cancer. The company's pipeline includes several promising candidates, including KIN-2787 and KIN-937. With a strong focus on innovation and collaboration, Kinnate aims to bring new treatments to patients in need. As a relatively new player in the industry, Kinnate has significant growth potential.","hq":"San Diego, CA","founded":0,"employees":"","ceo":"Nima Farzan","sector":"Precision Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$180M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":90767000,"netIncome":-112649000,"cash":56998000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2033-06-01","label":"KIN-2787 patent cliff ($0.0B at risk)","drug":"KIN-2787","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"KIN-937 patent cliff ($0.0B at risk)","drug":"KIN-937","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Kinnate Biopharma Announces FDA Fast Track Designation for KIN-2787","summary":"KIN-2787, a potent and selective inhibitor of the FGFR4 kinase, has been granted Fast Track designation by the FDA for the treatment of FGFR4-driven cancers.","drugName":"KIN-2787","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Kinnate Biopharma Reports Third Quarter 2023 Financial Results","summary":"Kinnate reported a net loss of $34.4 million for the third quarter of 2023, with research and development expenses increasing to $24.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-31","type":"deal","headline":"Kinnate Biopharma Announces Collaboration with Merck KGaA to Develop Cancer Therapies","summary":"Kinnate has entered into a collaboration with Merck KGaA to develop and commercialize several cancer therapies, including KIN-2787.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQWWl1by12WlJ1bHk1SDd3azJEOUhfX0szbldiUDNWUWs4TWZKak1Fc3VFeWJzRXlsUFhmRFNlMjE2UTlPLXN0QWJJTFpVa3Z4NnBVTUtkdHVjSWhfS3hsc01aUmVWcjJManJaem1ueFlsQlphZFBMTFVGbWNtYVRjTGtEeXplSWg1MnJpSmVPWFVrTDhaMlo0?oc=5","date":"2026-03-04","type":"pipeline","source":"The Pharma Letter","summary":"Latigo appoints Neha Krishnamohan as CFO and CBO - The Pharma Letter","headline":"Latigo appoints Neha Krishnamohan as CFO and CBO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBaR1RHaW01MWdvZ2dJYmVvWWJudUJmM08xc3dUVFd0dW1zUndUZFB1Q3NEeEZMVDl0RnpjSFpuN0pEdXhnaUpSdlJyeTMyNU5KRnBn?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"KNTE Stock Price, News & Analysis - Stock Titan","headline":"KNTE Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxNTktLY2FidlAwNGR2a0ROTEJuVWswQWhORGFOSEJFUUxfN0kyNjM4ZFlYSWtSdlByckpyOEMwamU0YTJBc2V5V2hMUjYtSklpOHpqdzE1bzJGeWllSHNPTTRoTG5PVER6Wm9QaXhYWE16S1NFTXBKOXB5U1lhTGFlRy1OajJwMWZOc1puakwtWWhNUU5ONzd0NFpVdENvOGZfYXFYb00yajRpN3ktWXlJTXFtUXpMNG41NUNFS3Z6bHIxQXFEREhfMGVnTDBua05TN0xXeXYyZXJyMmJiMlBCNE9Xbk9lVlgyZjF0Z29zYXBEc3hqcElXS1hxbndqUWQxYXlYWXJocEpDQ2d0aVljNk1rVU8wZjg?oc=5","date":"2024-10-18","type":"pipeline","source":"BioSpace","summary":"Eric Murphy, Ph.D., Co-Founder and CEO of Alterome, Named to Goldman Sachs Top 100 Most Exceptional Entrepreneurs at 2024 Builders and Innovators Summit - BioSpace","headline":"Eric Murphy, Ph.D., Co-Founder and CEO of Alterome, Named to Goldman Sachs Top 100 Most Exceptional Entrepreneurs at 202","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNMzlQV0NaX1J6RGxzMWVMdURjYWpoTl92dDlYZWRPNjlqaXVVZTM4WTNGOGtTUWViUjVqR1JkSmM1RUpGMUtWbjNKV3YyRk43cjRsVVpWQXk4VVFtMDl6b1ktQXlIWFBaNGpKbFR6S0g4dzZER3ItRy1rUTdiQklacjdTWmRvS2wzRGMxRUdMUVY5dEc1MXR5c3ZUS0RTb2FiT1l1NFlpYUwtdG96ZVQ5dUNKcW9jMXJEUGM4MUNn?oc=5","date":"2024-04-01","type":"patent","source":"Fierce Pharma","summary":"Patented AI Platform Identifies Promising Early-Stage BioPharma Assets and Companies - Fierce Pharma","headline":"Patented AI Platform Identifies Promising Early-Stage BioPharma Assets and Companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxQcl9DT04yTkgzQVhwLWZfRjF1VjdXOVQyd0RJdlQ1ZGc5SDZTOFV1RmpsVzhGUHNJR3NIR3B1VmZCQW5URFFVRF9YaklxdnJqRFVRdkkteGI5UjRJdUNiZWFrSFRhaURuM1duOElFMFVIUGVzU1NYcWN6WExwUDFNbnlTTHJ1ZG9hX1F4ZVRYbXgyYW1pWjFFTDY3eFR4NWRuaGdYOTVINzhYSXltLS1EZ3NRTXFqZEt5VnZ4TTJpWnhMSWluS3F3SVhFRTdMcUdXRmdhc19RSDd0Y2RmM2FKYW04NjdmR0MtVzE5UjB2Q2hiYWc?oc=5","date":"2024-03-01","type":"pipeline","source":"PR Newswire","summary":"Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories - PR Newswire","headline":"Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxOOUk2WVBfT0YtNlJFcUtDZzJsOGs5cEx5OTRRYXd6UUVYSDNxWGZzYjl6MXgweURVcHppY054U0duU0Mya0Z6QWdwVGdvOU1YOFRMWERRTi05aEJ5Q3lvdlZldXVwektFWkRIak5IRGFJWlp4VTljT0FJVF9icVZOYWtnZGF4bDRNZzliQnVTVHAzNm11N3MtSy1lMmRGQTAzMWpxdFlyeE41WmI2RV9Ca3hfQnpSTVFEVGthVTNiWHZqYlNWMm4xWWlRbU92ZmZUalAyYkhBb2ZsN29scTZjYXBBcWc4NUNCcWRXcXRQU1hUbmF6NkhYdklkTlRGR2JCV3laaUl4TGgtMi1STVVtcHJ0S3A0QndNQ2JWMTBlSkFleVpQb3hZamE3Qk5reVQ4VVE?oc=5","date":"2024-02-16","type":"deal","source":"GlobeNewswire","summary":"XOMA Enters into Agreement to Acquire Kinnate Biopharma for - GlobeNewswire","headline":"XOMA Enters into Agreement to Acquire Kinnate Biopharma for","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-02-21","type":"pipeline","source":"GlobeNewswire","summary":"Kinnate Biopharma Inc. Announces Acquisition of Ownership - GlobeNewswire","headline":"Kinnate Biopharma Inc. Announces Acquisition of Ownership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5MNEJUTk9JbXBKSjBnNkF5eWFfOC1fd2ZYUldSVVpXQlZZcER0ckp6V2luU0FoYzFZRW5pUHF5bkI0ZzA1R2dFTG83YlJJVTJvWGNNY3Fkd2tKSDkxNmxZ?oc=5","date":"2021-03-31","type":"pipeline","source":"ChartMill","summary":"KNTE Stock Price, Quote & Chart | KINNATE BIOPHARMA INC (NASDAQ:KNTE) - ChartMill","headline":"KNTE Stock Price, Quote & Chart | KINNATE BIOPHARMA INC (NASDAQ:KNTE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPSGcxZEVTZTZSRlZmOXlPMXFMTEVsLWotNEl5X2JPemIwYWRIcXlPemR3X012bHkyUXh5dEJ2SjI1MDQ5NWxDTS1ZUGZoSVc0T0dsZXFxdGJnQ2dTbTBQVjJaS2VTdERWOWc5aEZENzc0REx5WElSckE5bm5pTF8xeQ?oc=5","date":"2020-12-05","type":"pipeline","source":"marketscreener.com","summary":"Kinnate Biopharma Inc. Stock (KNTE) - Quote Nasdaq - marketscreener.com","headline":"Kinnate Biopharma Inc. Stock (KNTE) - Quote Nasdaq","sentiment":"neutral"}],"patents":[{"drugName":"KIN-2787","drugSlug":"fgfr4-inhibitor","patentNumber":"","type":"Patent Cliff","expiryDate":"2033-06-01","territory":"US","annualRevenue":0},{"drugName":"KIN-937","drugSlug":"bcma-targeting-antibody","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","AstraZeneca"],"therapeuticFocus":["Precision Oncology","Cancer Therapies"],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":90767000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-112649000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":56998000,"cashHistory":[],"totalAssets":173605000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}